NEW YORK, NY / ACCESSWIRE / November 9, 2017 / Ophthotech and HTG Molecular Diagnostics both saw green on Wednesday after announcing strong third quarter reports. Ophthotech also announced that it is on track to have four trials ongoing by the end this year.

RDI Initiates Coverage on:

Ophthotech Corporation
https://rdinvesting.com/news/?ticker=OPHT

HTG Molecular Diagnostics, Inc.
https://rdinvesting.com/news/?ticker=HTGM

Ophthotech Corporation shares closed up nearly 16% yesterday on a little over 7 million shares traded. The stock surged after the company released its Q3 report. For the quarter, Ophthotech reported net income of $189.1 million. This was an improvement compared to the loss in the year-ago quarter. EPS came in at $5.25 and revenue was $206.7 million. The biotech company focused on eye diseases was already gaining in pre-market trading after the release. CEO Glenn P. Sblendorio stated, "We are very excited to provide an update on the expansion of our age-related and orphan retina programs with our complement C5 inhibitor, Zimura. Scientific literature continues to strengthen our belief in the potential role of complement C5 inhibition in the treatment of retinal diseases. We have progressed in all of our clinical programs by initiating new trials and modifying a current clinical trial. We remain on track to have four trials ongoing by the end of the year."

Access RDI's Ophthotech Corporation Research Report at:
https://rdinvesting.com/news/?ticker=OPHT

HTG Molecular Diagnostics, Inc. shares closed up 13.84% yesterday on nearly 3.7 million shares traded. Traders seemed more than impressed by the company's third-quarter earnings. The provider of instruments, reagents, and services for molecular profiling applications, released its earnings for the three and nine-month periods ended September 30, 2017. Revenues saw a gain of 307% and 87% respectively at $3.7 million and $6.9 million for the 3-months and 9-month period ending September 30, 2017. The Arizona-based company also announced that it has signed a second statement of work under the company?s Master Assay Development, Commercialization and Manufacturing Agreement with Qiagen Manchester Limited, (QML). It also signed a Supplement Agreement with QML and Bristol-Myers Squibb Company (BMS).

Access RDI's HTG Molecular Diagnostics, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=HTGM

Our Actionable Research on Ophthotech Corporation (NASDAQ: OPHT) and HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com